To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Notification of transactions by persons discharging managerial responsibilities and persons closely associated

Release Date: 22/06/2020 17:00
Code(s): MEI     PDF:  
Wrap Text
Notification of transactions by persons discharging managerial responsibilities and persons closely associated

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", or the "Company", or the "Group")

22 June 2020

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 19 June 2020, Mr Gert Hattingh, Group Chief Corporate Services Officer of Mediclinic International
plc, sold a total of 25 904 shares in the Company to cover personal tax liabilities. Mr Hattingh continues
to hold 100 000 shares in the Company.

The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.

  1.      Details of PDMR / person closely associated with them (“PCA”)
  a)      Name                     Ghwarriebos Investments (Pty) Ltd

  2.      Reason for the notification
  a)      Position / status        PCA of Mr Gert Cornelis Hattingh, Group Chief Corporate
                                   Services Officer
  b)      Initial notification /   Initial Notification
          amendment

  3.      Details of the issuer, emission allowance market participant, auction platform, auctioneer or
          auction monitor
  a)      Name                     Mediclinic International plc
  b)      LEI                      2138002S5BSBIZTD5I60

  4.      Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
          type of transaction; (iii) each date; and (iv) each place where transactions have been
          conducted
  a)      Description of the       Ordinary Shares
          financial instrument
          Identification Code      GB00B8HX8Z88
  b)      Nature of the            Sale of shares
          transaction
  c)      Price(s) and
          volume(s)                  Price(s) per share                Volume(s)
                                     ZAR 58.37                         4 000
                                     ZAR 58.43                         3 000
                                     ZAR 58.46                         3 055
                                     ZAR 58.47                         1 904
                                     ZAR 58.48                         945
                                     ZAR 58.50                         4 000
                                     ZAR 58.55                         2 000
                                     ZAR 58.58                         3 000
                                     ZAR 58.73                         3 500
                                     ZAR 58.74                         500
  d)       Aggregated
           information
           Aggregated volume         25 904
           Price                     ZAR 58.51 per share
  e)       Date of the               19 June 2020; 11:12 UTC
           transaction
  f)       Place of the              Johannesburg Stock Exchange
           transaction



About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates
("UAE").

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.

At 1 June 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day
case clinics and 21 outpatient clinics. Hirslanden operated 17 hospitals, three day case clinics and three
outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern
Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised
hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more
than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics
and 18 outpatient clinics with more than 900 inpatient beds in the UAE.

The Company’s primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with
secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.


For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9548

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 22-06-2020 05:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story